Login / Signup

Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact.

Stefan JungbluthWilliam MartinMonika SlezakHilde DepraetereCarlos Alberto GuzmánAnton UssiDavid MorrowFran Van HeuverswynSven ArnoutsManuel J T CarrondoOle OlesenTom H M OttenhoffH M DockrellMei Mei HoAlexandre DoblyDennis ChristensenJoaquim SegalésFabrice LaurentFrédéric LantierNorbert Stockhofe-ZurwiedenFrancesca MorelliJan A M LangermansFrank A W VerreckRoger Le GrandArjen SlootsDonata MedagliniMaria LawrenzNicolas Collin
Published in: F1000Research (2023)
The business model we have developed, the impact assessment and the overall process we have followed might also be of interest to other research infrastructure initiatives in the biomedical field.
Keyphrases
  • quality improvement
  • risk assessment